223 related articles for article (PubMed ID: 32945525)
1. COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience.
Pike A; Muus P; Munir T; Mitchell L; Arnold L; Riley K; Houghton N; Forrest B; Gachev J; Hillmen P; Griffin M
Br J Haematol; 2020 Oct; 191(1):e1-e4. PubMed ID: 32945525
[No Abstract] [Full Text] [Related]
2. Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report.
Schüller H; Klein F; Lübbert M; Prager EP
Ann Hematol; 2021 Mar; 100(3):841-842. PubMed ID: 33170342
[No Abstract] [Full Text] [Related]
3. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
[No Abstract] [Full Text] [Related]
4. Neisseria elongata infection associated with complement inhibition during treatment of paroxysmal nocturnal haemoglobinuria.
Benz R; Krause M; Majer S; Taverna C; Herzog K
Br J Haematol; 2018 Aug; 182(3):318. PubMed ID: 29676447
[No Abstract] [Full Text] [Related]
5. COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria.
Pravdic Z; Mitrovic M; Bogdanovic A; Virijevic M; Sabljic N; Pantic N; Vukovic NS
Hamostaseologie; 2021 Oct; 41(5):397-399. PubMed ID: 34544179
[TBL] [Abstract][Full Text] [Related]
6. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.
Araten DJ; Belmont HM; Schaefer-Cutillo J; Iyengar A; Mattoo A; Reddy R
Am J Case Rep; 2020 Sep; 21():e927418. PubMed ID: 32917848
[TBL] [Abstract][Full Text] [Related]
7. [With paroxysmal nocturnal haemoglobinuria and treatment with eculizumab].
Algado JT; Luque R; Nuñez R; Sanchez B
Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):109-10. PubMed ID: 22197277
[No Abstract] [Full Text] [Related]
8. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
[No Abstract] [Full Text] [Related]
9. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
Guasch A
Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585
[No Abstract] [Full Text] [Related]
10. Terminal complement inhibition dampens the inflammation during COVID-19.
Kulasekararaj AG; Lazana I; Large J; Posadas K; Eagleton H; Lord Villajin J; Zuckerman M; Gandhi S; Marsh JCW
Br J Haematol; 2020 Aug; 190(3):e141-e143. PubMed ID: 32495372
[No Abstract] [Full Text] [Related]
11. Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria.
Waheed A; Kuter DJ
Am J Hematol; 2021 Jul; 96(7):E235-E237. PubMed ID: 33844861
[No Abstract] [Full Text] [Related]
12. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey.
Barcellini W; Fattizzo B; Giannotta JA; Quattrocchi L; Aydin S; Barone F; Carbone C; Pomponi F; Metafuni E; Beggiato E; Sica S; Di Bona E; Lanza F; Notaro R; Iori AP
Br J Haematol; 2021 Sep; 194(5):854-856. PubMed ID: 34036575
[No Abstract] [Full Text] [Related]
14. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
McQuillen DP; Ram S
Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
[No Abstract] [Full Text] [Related]
15. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.
Gerber GF; Yuan X; Yu J; Cher BAY; Braunstein EM; Chaturvedi S; Brodsky RA
Blood; 2021 Jul; 137(26):3670-3673. PubMed ID: 33945618
[No Abstract] [Full Text] [Related]
16. Effective eculizumab therapy followed by BMT in a boy with paroxysmal nocturnal hemoglobinuria.
Oshiro H; Goi K; Akahane K; Inukai T; Sugita K
Pediatr Int; 2015 Apr; 57(2):e27-9. PubMed ID: 25868955
[TBL] [Abstract][Full Text] [Related]
17. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
19. An unusual presentation of paroxysmal nocturnal haemoglobinuria.
Sanchez-Petitto G; Drachenberg CB; Mannuel HD; Law JY; Zimrin AB; Baer MR
Br J Haematol; 2020 Feb; 188(3):347. PubMed ID: 31750542
[No Abstract] [Full Text] [Related]
20. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
Socié G; Caby-Tosi MP; Marantz JL; Cole A; Bedrosian CL; Gasteyger C; Mujeebuddin A; Hillmen P; Vande Walle J; Haller H
Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
